N-Arachidonyl Maleimide Potentiates the Pharmacological and Biochemical Effects of the Endocannabinoid 2-Arachidonylglycerol through Inhibition of Monoacylglycerol Lipase-Reference-Cited by-同舟云学术

N-Arachidonyl Maleimide Potentiates the Pharmacological and Biochemical Effects of the Endocannabinoid 2-Arachidonylglycerol through Inhibition of Monoacylglycerol Lipase

Published:2008-08-05 Issue:2 Volume:327 Page:546-553
ISSN:0022-3565
Container-title:Journal of Pharmacology and Experimental Therapeutics
language:en
Short-container-title:J Pharmacol Exp Ther

Author:

Burston James J.,Sim-Selley Laura J.,Harloe John P.,Mahadevan Anu,Razdan Raj K.,Selley Dana E.,Wiley Jenny L.

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference39 articles.

1. Critical Enzymes Involved in Endocannabinoid Metabolism

2. A Comprehensive Profile of Brain Enzymes that Hydrolyze the Endocannabinoid 2-Arachidonoylglycerol

3. Fatty acid amide hydrolase substrate specificity

4. Novel, potent THC/anandamide (hybrid) analogs

5. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhibiting degradation of 2-arachidonoylglycerol as a therapeutic strategy for neurodegenerative diseases;Pharmacology & Therapeutics;2023-04

2. Targeting Peripherally Restricted Cannabinoid Receptor 1, Cannabinoid Receptor 2, and Endocannabinoid-Degrading Enzymes for the Treatment of Neuropathic Pain Including Neuropathic Orofacial Pain;International Journal of Molecular Sciences;2020-02-20

3. Monoacylglycerol lipase (MAGL) as a promising therapeutic target;Biochemical Pharmacology;2018-11

4. Inhibition of 2-arachydonoylgycerol degradation attenuates orofacial neuropathic pain in trigeminal nerve-injured mice;Journal of Oral Science;2018

5. In Vivo Characterization of the Ultrapotent Monoacylglycerol Lipase Inhibitor (1H-1,2,4-triazol-1-yl)methanone (JJKK-048);Journal of Pharmacology and Experimental Therapeutics;2016-07-22